Occudo Quantitative Strategies LP Purchases 630 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Occudo Quantitative Strategies LP raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 5.8% during the 4th quarter, HoldingsChannel reports. The fund owned 11,441 shares of the biopharmaceutical company’s stock after buying an additional 630 shares during the quarter. Occudo Quantitative Strategies LP’s holdings in Xenon Pharmaceuticals were worth $448,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Prudential Financial Inc. lifted its stake in Xenon Pharmaceuticals by 177.7% in the 4th quarter. Prudential Financial Inc. now owns 39,000 shares of the biopharmaceutical company’s stock valued at $1,529,000 after acquiring an additional 24,956 shares in the last quarter. Barclays PLC increased its position in shares of Xenon Pharmaceuticals by 1,275.5% during the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $590,000 after purchasing an additional 13,903 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Xenon Pharmaceuticals by 12.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 238,522 shares of the biopharmaceutical company’s stock worth $9,350,000 after purchasing an additional 26,235 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Xenon Pharmaceuticals by 38.9% during the 4th quarter. JPMorgan Chase & Co. now owns 1,356,895 shares of the biopharmaceutical company’s stock worth $53,190,000 after purchasing an additional 380,112 shares during the last quarter. Finally, Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth approximately $101,000. Institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on XENE. Wells Fargo & Company lowered their price target on Xenon Pharmaceuticals from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Tuesday. The Goldman Sachs Group decreased their target price on Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating on the stock in a report on Thursday, April 17th. Evercore ISI began coverage on Xenon Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $55.00 target price on the stock. Chardan Capital reissued a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price target for the company. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $54.82.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE opened at $29.57 on Friday. The stock has a fifty day moving average price of $34.19 and a 200-day moving average price of $38.03. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -10.49 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same quarter in the previous year, the company posted ($0.62) earnings per share. Research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.